Exploratory biomarker analysis for predicting treatment effects of aflibercept in the VELOUR trial.

被引：0
|
作者：
Pu, Ting
Peddle, Allyson
Wirapati, Pratyaksha
Hong, Yourae
Samuel, Leslie
Desai, Jayesh
Riener, Maigo
Saridaki, Zacharenia
Cunningham, David
Tejpar, Sabine
Tsantoulis, Petros
机构：
[1] Katholieke Univ Leuven, Leuven, Belgium
[2] Swiss Inst Bioinformat, Lausanne, Switzerland
[3] Aberdeen Royal Infirm, Aberdeen, Scotland
[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[5] Docrates Canc Hosp Helsinki, Helsinki, Finland
[6] Metropolitan Hosp, Athens, Greece
[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[8] Katholieke Univ Leuven, UZ Gasthuisberg, Leuven, Belgium
[9] Geneva Univ Hosp, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3592
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Regorafenib in metastatic colorectal cancer: An exploratory biomarker trial.
    Salem, Mohamed E.
    Petricoin, Emanuel
    Wellstein, Anton
    Pierobon, Mariaelena
    Wang, Hongkun
    Mikhail, Sameh
    Hartley, Marion L.
    Smaglo, Brandon George
    Lou, Emil
    Alistar, Angela Tatiana
    Dorsch-Vogel, Karen
    Pishvaian, Michael J.
    He, Aiwu Ruth
    Kim, Alexander Y.
    Shivapurkar, Narayan
    Reddy, Sandeep K.
    Marshall, John
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Impact of Prior Bevacizumab Treatment on VEGF-A and PIGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
    Van Cutsem, Eric
    Paccard, Caroline
    Chiron, Marielle
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2020, 26 (03) : 717 - 725
  • [3] Placental growth factor and the angiogenic environment based on analysis of baseline plasma biomarkers from the VELOUR trial.
    Tabernero, Josep
    Paccard, Caroline
    Chiron, Marielle
    Dochy, Emmanuelle
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment
    Ruff, Paul
    Lakomy, Radek
    Prausova, Jana
    Van Hazel, Guy
    Moiseyenko, Vladimir Mikhailovich
    Bhargava, Pankaj
    Tabernero, Josep
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [5] Documentation patterns and impact on observed side effects of the CANKADO ehealth application: An exploratory analysis of the PreCycle trial.
    Degenhardt, Tom
    Harbeck, Nadia
    Fasching, Pater A.
    Wuerstlein, Rachel
    Lueftner, Diana
    Kates, Ronald E.
    Schumacher, Johannes
    Wenzel, Claudia
    Schinkoethe, Timo
    Schmidt, Marcus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Ian Chau
    Florence Joulain
    Sheikh Usman Iqbal
    John Bridgewater
    BMC Cancer, 14
  • [7] A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
    Chau, Ian
    Joulain, Florence
    Iqbal, Sheikh Usman
    Bridgewater, John
    BMC CANCER, 2014, 14
  • [8] Predicting treatment effects using biomarker data in a meta-analysis of clinical trials
    Li, Y.
    Taylor, J. M. G.
    STATISTICS IN MEDICINE, 2010, 29 (18) : 1875 - 1889
  • [9] Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
    Tabernero, Josep
    Van Cutsem, Eric
    Lakomy, Radek
    Prausova, Jana
    Ruff, Paul
    van Hazel, Guy A.
    Moiseyenko, Vladimir M.
    Ferry, David R.
    McKendrick, Joseph J.
    Soussan-Lazard, Karen
    Chevalier, Soazig
    Allegra, Carmen J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) : 320 - 331
  • [10] Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment
    Ruff, Paul
    Lakomy, Radek
    Prausova, Jana
    Van Hazel, Guy A.
    Moiseyenko, Vladimir
    McKendrick, Joseph
    Boelle, Emmanuelle
    Castan, Remi
    Macarulla, Teresa
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345